Oncology News

Geisinger, a health system that serves more than 3 million residents throughout the eastern half of Pennsylvania and southern New Jersey, made medical history in the United States when it started routine DNA screening in July.

The risk for hepatocellular carcinoma was higher among patients with nonalcoholic fatty liver disease, especially those with cirrhosis, compared with the general clinical population, according to a study published in Gastroenterology.

Results of a recent mortality profile of New York City residents with hepatitis C and hepatitis B showed that patients with HCV were significantly more likely to have HIV coinfection, hepatocellular carcinoma, and lower survival rates compared with HBV.

In August, the FDA issued several approvals and review designations across the field of oncology. HemOnc Today has compiled a list of the past month’s approvals, updates and submissions.

Liver disease researchers recently published internally validated models that estimated the risk for hepatocellular carcinoma following direct-acting antiviral therapy for hepatitis C based on the presence of cirrhosis and sustained virologic response outcome.

The American College of Radiology Liver Imaging Reporting and Data System steering committee developed and approved a new version of the CT/MRI LI-RADS — a comprehensive system for standardizing the acquisition, interpretation, reporting and data collection of liver imaging — according to a press release.

Lion TCR received approval from the Health Sciences Authority in Singapore to perform a phase 1/2 multicenter clinical study of its LioCyx candidate for treating liver cancer relapse after liver transplant, according to a press release.

The presence of a satellite nodule or peritumoral hypointensity in the hepatobiliary phase during preoperative hepatobiliary magnetic resonance imaging correlated with a high rate of recurrence among patients both within and outside Milan criteria who underwent liver transplantation for hepatocellular carcinoma, according to recently published data.

Screening patients with cirrhosis for hepatocellular carcinoma using either or both abdominal ultrasonography and serum alpha fetoprotein did not correlate with decreased HCC-related mortality, according to a study recently published in Gastroenterology.

The FDA approved lenvatinib capsules for the first-line treatment of patients with unresectable hepatocellular carcinoma.